This educational activity is provided by Haymarket Medical Education.
Supported by an educational grant from Teva Pharmaceuticals
Chronic pain exerts a profoundly negative impact on virtually every domain of life and can be considered a disease unto itself. Although opioid analgesics are highly effective in reducing the symptoms of chronic pain, this class of medication is associated with risks that include abuse, misuse, and diversion. Strategies for safe, effective opioid therapy include thoughtful patient evaluation and a shared decision-making approach to care, as well as the use of available and emerging abuse-deterrent opioid formulations.
Pain specialists and other clinicians who provide care for patients with chronic pain
At the conclusion of this activity, participants should be better able to:
Evaluate patients with chronic pain to identify those who may benefit from opioid therapy
Stratify patients with chronic pain according to low, moderate, or high risk for opioid misuse, abuse, or diversion
Individualize chronic pain treatment plans with attention to medication choice and dosing strategies intended to optimize outcomes and minimize risk
Communicate effectively with patients who experience chronic pain to facilitate a shared decision-making model of care
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty Chair Jeffrey A. Gudin, MD Director, Pain Management and Palliative Care Englewood Hospital and Medical Center Englewood, NJ Clinical Instructor in Anesthesiology Icahn School of Medicine at Mount Sinai New York, NY
Dr. Gudin is a consultant for AstraZeneca, Depomed, Inc., Iroko Pharmaceuticals, Kaleo Pharma, Kempharm, Inc., Purdue Pharma, Quest Diagnostics, Scilex Pharmaceuticals, and Teva Pharmaceuticals. Dr Gudin serves on the speakers’ bureaus of AstraZeneca, Depomed, Inc., Iroko Pharmaceuticals, Kaleo Pharma, Purdue Pharma, and Teva Pharmaceuticals.
Charles E. Argoff, MD Professor of Neurology Albany Medical College Director, Comprehensive Pain Center Albany Medical Center Albany, NY
Dr. Argoff receives grant/research support from Endo Pharmaceuticals, Forest Laboratories, Inc., and Lilly USA. He is a consultant for Ameritox, Collegium Pharmaceutical, Daiichi Sankyo, Inc., Depomed, Inc., Endo Pharmaceuticals, Lilly USA, ORx Pharmaceutical Corporation, and Teva Neurosciences. Dr. Argoff serves on the speakers’ bureaus of Allergan, Inc., Depomed, Inc., Endo Pharmaceuticals, Lilly USA, Millennium Pharmaceuticals, Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Steven P. Stanos, Jr., DO Medical Director of Swedish Pain Services Medical Director of Occupational Medicine Services Swedish Health System Seattle, WA
Dr. Stanos is a consultant for Daiichi Sankyo, Endo Pharmaceuticals, myMatrixx, Pfizer, Purdue Pharma, and Scilex Pharmaceuticals.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only those credits commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Teva Pharmaceuticals and Haymarket Medical Education do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Teva Pharmaceuticals and Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.